nodes	percent_of_prediction	percent_of_DWPC	metapath
Nepafenac—PTGS2—prostate cancer	0.515	1	CbGaD
Nepafenac—PTGS2—Etoposide—prostate cancer	0.0548	0.542	CbGbCtD
Nepafenac—PTGS1—Etoposide—prostate cancer	0.0463	0.458	CbGbCtD
Nepafenac—Mefenamic acid—AKR1C3—prostate cancer	0.00109	0.112	CrCbGaD
Nepafenac—Carbamazepine—RALBP1—prostate cancer	0.00103	0.106	CrCbGaD
Nepafenac—Sinusitis—Ethinyl Estradiol—prostate cancer	0.000883	0.00418	CcSEcCtD
Nepafenac—Hypertension—Cabazitaxel—prostate cancer	0.000876	0.00415	CcSEcCtD
Nepafenac—Nervous system disorder—Degarelix—prostate cancer	0.000862	0.00408	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Cabazitaxel—prostate cancer	0.000858	0.00406	CcSEcCtD
Nepafenac—Skin disorder—Degarelix—prostate cancer	0.000854	0.00404	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Nilutamide—prostate cancer	0.000849	0.00402	CcSEcCtD
Nepafenac—Dry mouth—Cabazitaxel—prostate cancer	0.000845	0.004	CcSEcCtD
Nepafenac—Eye irritation—Docetaxel—prostate cancer	0.000828	0.00392	CcSEcCtD
Nepafenac—Dermatitis atopic—Prednisone—prostate cancer	0.000824	0.0039	CcSEcCtD
Nepafenac—Arthritis—Estradiol—prostate cancer	0.00082	0.00388	CcSEcCtD
Nepafenac—Nervous system disorder—Cabazitaxel—prostate cancer	0.000812	0.00385	CcSEcCtD
Nepafenac—Lacrimation—Epirubicin—prostate cancer	0.000811	0.00384	CcSEcCtD
Nepafenac—Skin disorder—Cabazitaxel—prostate cancer	0.000804	0.00381	CcSEcCtD
Nepafenac—Eye irritation—Capecitabine—prostate cancer	0.000802	0.0038	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Estradiol valerate/Dienogest—prostate cancer	0.000798	0.00378	CcSEcCtD
Nepafenac—Eye disorder—Ethinyl Estradiol—prostate cancer	0.00079	0.00374	CcSEcCtD
Nepafenac—Pruritus—Estramustine—prostate cancer	0.000784	0.00372	CcSEcCtD
Nepafenac—Lacrimation increased—Docetaxel—prostate cancer	0.000767	0.00364	CcSEcCtD
Nepafenac—Angiopathy—Ethinyl Estradiol—prostate cancer	0.000767	0.00363	CcSEcCtD
Nepafenac—Immune system disorder—Ethinyl Estradiol—prostate cancer	0.000763	0.00362	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Degarelix—prostate cancer	0.000759	0.0036	CcSEcCtD
Nepafenac—Hypertension—Bicalutamide—prostate cancer	0.000751	0.00356	CcSEcCtD
Nepafenac—Lacrimation—Doxorubicin—prostate cancer	0.000751	0.00356	CcSEcCtD
Nepafenac—Pruritus—Estrone—prostate cancer	0.000749	0.00355	CcSEcCtD
Nepafenac—Lacrimation increased—Capecitabine—prostate cancer	0.000743	0.00352	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Bicalutamide—prostate cancer	0.000736	0.00349	CcSEcCtD
Nepafenac—Keratitis—Epirubicin—prostate cancer	0.000735	0.00348	CcSEcCtD
Nepafenac—Sinusitis—Goserelin—prostate cancer	0.000727	0.00344	CcSEcCtD
Nepafenac—Dry mouth—Bicalutamide—prostate cancer	0.000725	0.00343	CcSEcCtD
Nepafenac—Sinusitis—Conjugated Estrogens—prostate cancer	0.00072	0.00341	CcSEcCtD
Nepafenac—Cataract—Capecitabine—prostate cancer	0.000719	0.00341	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Cabazitaxel—prostate cancer	0.000715	0.00339	CcSEcCtD
Nepafenac—Blood pressure increased—Docetaxel—prostate cancer	0.000707	0.00335	CcSEcCtD
Nepafenac—Vomiting—Estramustine—prostate cancer	0.000705	0.00334	CcSEcCtD
Nepafenac—Dizziness—Estrone—prostate cancer	0.0007	0.00332	CcSEcCtD
Nepafenac—Nervous system disorder—Bicalutamide—prostate cancer	0.000697	0.0033	CcSEcCtD
Nepafenac—Pruritus—Nilutamide—prostate cancer	0.000696	0.0033	CcSEcCtD
Nepafenac—Headache—Estramustine—prostate cancer	0.000695	0.00329	CcSEcCtD
Nepafenac—Pruritus—Flutamide—prostate cancer	0.000693	0.00328	CcSEcCtD
Nepafenac—Skin disorder—Bicalutamide—prostate cancer	0.00069	0.00327	CcSEcCtD
Nepafenac—Vomiting—Abiraterone—prostate cancer	0.000685	0.00324	CcSEcCtD
Nepafenac—Blood pressure increased—Capecitabine—prostate cancer	0.000685	0.00324	CcSEcCtD
Nepafenac—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.000681	0.00323	CcSEcCtD
Nepafenac—Keratitis—Doxorubicin—prostate cancer	0.00068	0.00322	CcSEcCtD
Nepafenac—Vomiting—Estrone—prostate cancer	0.000673	0.00319	CcSEcCtD
Nepafenac—Headache—Estrone—prostate cancer	0.000664	0.00314	CcSEcCtD
Nepafenac—Nausea—Estramustine—prostate cancer	0.000659	0.00312	CcSEcCtD
Nepafenac—Pruritus—Estradiol valerate/Dienogest—prostate cancer	0.000654	0.0031	CcSEcCtD
Nepafenac—Dizziness—Nilutamide—prostate cancer	0.000651	0.00308	CcSEcCtD
Nepafenac—Eye disorder—Goserelin—prostate cancer	0.00065	0.00308	CcSEcCtD
Nepafenac—Dizziness—Flutamide—prostate cancer	0.000648	0.00307	CcSEcCtD
Nepafenac—Hypersensitivity—Degarelix—prostate cancer	0.000648	0.00307	CcSEcCtD
Nepafenac—Dermatitis atopic—Epirubicin—prostate cancer	0.000644	0.00305	CcSEcCtD
Nepafenac—Eye disorder—Conjugated Estrogens—prostate cancer	0.000644	0.00305	CcSEcCtD
Nepafenac—Cataract—Prednisone—prostate cancer	0.000641	0.00304	CcSEcCtD
Nepafenac—Dry eye—Capecitabine—prostate cancer	0.000632	0.003	CcSEcCtD
Nepafenac—Angiopathy—Goserelin—prostate cancer	0.000631	0.00299	CcSEcCtD
Nepafenac—Nausea—Estrone—prostate cancer	0.000629	0.00298	CcSEcCtD
Nepafenac—Immune system disorder—Goserelin—prostate cancer	0.000628	0.00298	CcSEcCtD
Nepafenac—Vomiting—Nilutamide—prostate cancer	0.000626	0.00296	CcSEcCtD
Nepafenac—Angiopathy—Conjugated Estrogens—prostate cancer	0.000625	0.00296	CcSEcCtD
Nepafenac—Vomiting—Flutamide—prostate cancer	0.000623	0.00295	CcSEcCtD
Nepafenac—Immune system disorder—Conjugated Estrogens—prostate cancer	0.000622	0.00295	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—prostate cancer	0.000622	0.00295	CcSEcCtD
Nepafenac—Pruritus—Degarelix—prostate cancer	0.000622	0.00295	CcSEcCtD
Nepafenac—Headache—Nilutamide—prostate cancer	0.000616	0.00292	CcSEcCtD
Nepafenac—Headache—Flutamide—prostate cancer	0.000614	0.00291	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Bicalutamide—prostate cancer	0.000613	0.00291	CcSEcCtD
Nepafenac—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.000611	0.0029	CcSEcCtD
Nepafenac—Hypersensitivity—Cabazitaxel—prostate cancer	0.00061	0.00289	CcSEcCtD
Nepafenac—Dermatitis atopic—Doxorubicin—prostate cancer	0.000596	0.00282	CcSEcCtD
Nepafenac—Nervous system disorder—Ethinyl Estradiol—prostate cancer	0.000589	0.00279	CcSEcCtD
Nepafenac—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.000588	0.00278	CcSEcCtD
Nepafenac—Nausea—Nilutamide—prostate cancer	0.000584	0.00277	CcSEcCtD
Nepafenac—Skin disorder—Ethinyl Estradiol—prostate cancer	0.000583	0.00276	CcSEcCtD
Nepafenac—Nausea—Flutamide—prostate cancer	0.000582	0.00276	CcSEcCtD
Nepafenac—Dizziness—Degarelix—prostate cancer	0.000581	0.00275	CcSEcCtD
Nepafenac—Headache—Estradiol valerate/Dienogest—prostate cancer	0.000579	0.00274	CcSEcCtD
Nepafenac—Sinusitis—Estradiol—prostate cancer	0.000576	0.00273	CcSEcCtD
Nepafenac—Diabetes mellitus—Capecitabine—prostate cancer	0.000571	0.00271	CcSEcCtD
Nepafenac—Vision blurred—Goserelin—prostate cancer	0.000571	0.0027	CcSEcCtD
Nepafenac—Vision blurred—Conjugated Estrogens—prostate cancer	0.000565	0.00268	CcSEcCtD
Nepafenac—Vomiting—Degarelix—prostate cancer	0.000559	0.00265	CcSEcCtD
Nepafenac—Headache—Degarelix—prostate cancer	0.000551	0.00261	CcSEcCtD
Nepafenac—Eye pain—Capecitabine—prostate cancer	0.00055	0.00261	CcSEcCtD
Nepafenac—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.000549	0.0026	CcSEcCtD
Nepafenac—Dizziness—Cabazitaxel—prostate cancer	0.000547	0.00259	CcSEcCtD
Nepafenac—Sinusitis—Mitoxantrone—prostate cancer	0.000537	0.00254	CcSEcCtD
Nepafenac—Vomiting—Cabazitaxel—prostate cancer	0.000526	0.00249	CcSEcCtD
Nepafenac—Hypersensitivity—Bicalutamide—prostate cancer	0.000523	0.00248	CcSEcCtD
Nepafenac—Hypertension—Goserelin—prostate cancer	0.000523	0.00248	CcSEcCtD
Nepafenac—Nausea—Degarelix—prostate cancer	0.000522	0.00247	CcSEcCtD
Nepafenac—Headache—Cabazitaxel—prostate cancer	0.000519	0.00246	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	0.000518	0.00246	CcSEcCtD
Nepafenac—Lacrimation increased—Epirubicin—prostate cancer	0.000518	0.00245	CcSEcCtD
Nepafenac—Eye disorder—Estradiol—prostate cancer	0.000515	0.00244	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Goserelin—prostate cancer	0.000512	0.00243	CcSEcCtD
Nepafenac—Arthritis—Capecitabine—prostate cancer	0.000511	0.00242	CcSEcCtD
Nepafenac—Diabetes mellitus—Prednisone—prostate cancer	0.000509	0.00241	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—prostate cancer	0.000507	0.0024	CcSEcCtD
Nepafenac—Dry mouth—Goserelin—prostate cancer	0.000504	0.00239	CcSEcCtD
Nepafenac—Pruritus—Bicalutamide—prostate cancer	0.000502	0.00238	CcSEcCtD
Nepafenac—Angiopathy—Estradiol—prostate cancer	0.0005	0.00237	CcSEcCtD
Nepafenac—Immune system disorder—Estradiol—prostate cancer	0.000498	0.00236	CcSEcCtD
Nepafenac—Nausea—Cabazitaxel—prostate cancer	0.000492	0.00233	CcSEcCtD
Nepafenac—Diclofenac—CYP2C18—prostate cancer	0.000491	0.0507	CrCbGaD
Nepafenac—Nervous system disorder—Goserelin—prostate cancer	0.000485	0.0023	CcSEcCtD
Nepafenac—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.00048	0.00227	CcSEcCtD
Nepafenac—Skin disorder—Goserelin—prostate cancer	0.00048	0.00227	CcSEcCtD
Nepafenac—Lacrimation increased—Doxorubicin—prostate cancer	0.000479	0.00227	CcSEcCtD
Nepafenac—Skin disorder—Conjugated Estrogens—prostate cancer	0.000475	0.00225	CcSEcCtD
Nepafenac—Diclofenac—CXCL8—prostate cancer	0.00047	0.0486	CrCbGaD
Nepafenac—Dizziness—Bicalutamide—prostate cancer	0.00047	0.00223	CcSEcCtD
Nepafenac—Vomiting—Bicalutamide—prostate cancer	0.000452	0.00214	CcSEcCtD
Nepafenac—Mebendazole—CYP1A1—prostate cancer	0.000449	0.0464	CrCbGaD
Nepafenac—Headache—Bicalutamide—prostate cancer	0.000445	0.00211	CcSEcCtD
Nepafenac—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000442	0.0021	CcSEcCtD
Nepafenac—Dry eye—Epirubicin—prostate cancer	0.000441	0.00209	CcSEcCtD
Nepafenac—Pruritus—Ethinyl Estradiol—prostate cancer	0.000425	0.00201	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000423	0.002	CcSEcCtD
Nepafenac—Nausea—Bicalutamide—prostate cancer	0.000422	0.002	CcSEcCtD
Nepafenac—Vision blurred—Mitoxantrone—prostate cancer	0.000421	0.002	CcSEcCtD
Nepafenac—Ketoprofen—CXCL8—prostate cancer	0.000416	0.043	CrCbGaD
Nepafenac—Hypertension—Estradiol—prostate cancer	0.000414	0.00196	CcSEcCtD
Nepafenac—Dry eye—Doxorubicin—prostate cancer	0.000408	0.00193	CcSEcCtD
Nepafenac—Oxcarbazepine—CYP3A5—prostate cancer	0.000407	0.0421	CrCbGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.000406	0.00192	CcSEcCtD
Nepafenac—Dry mouth—Estradiol—prostate cancer	0.0004	0.00189	CcSEcCtD
Nepafenac—Eye disorder—Etoposide—prostate cancer	0.000399	0.00189	CcSEcCtD
Nepafenac—Diabetes mellitus—Epirubicin—prostate cancer	0.000398	0.00189	CcSEcCtD
Nepafenac—Dizziness—Ethinyl Estradiol—prostate cancer	0.000397	0.00188	CcSEcCtD
Nepafenac—Angiopathy—Etoposide—prostate cancer	0.000388	0.00184	CcSEcCtD
Nepafenac—Ketorolac—PTGS2—prostate cancer	0.000386	0.0399	CrCbGaD
Nepafenac—Hypertension—Mitoxantrone—prostate cancer	0.000386	0.00183	CcSEcCtD
Nepafenac—Immune system disorder—Etoposide—prostate cancer	0.000386	0.00183	CcSEcCtD
Nepafenac—Nervous system disorder—Estradiol—prostate cancer	0.000384	0.00182	CcSEcCtD
Nepafenac—Eye pain—Epirubicin—prostate cancer	0.000383	0.00182	CcSEcCtD
Nepafenac—Vomiting—Ethinyl Estradiol—prostate cancer	0.000382	0.00181	CcSEcCtD
Nepafenac—Skin disorder—Estradiol—prostate cancer	0.00038	0.0018	CcSEcCtD
Nepafenac—Headache—Ethinyl Estradiol—prostate cancer	0.000376	0.00178	CcSEcCtD
Nepafenac—Bromfenac—PTGS2—prostate cancer	0.000371	0.0383	CrCbGaD
Nepafenac—Diabetes mellitus—Doxorubicin—prostate cancer	0.000368	0.00174	CcSEcCtD
Nepafenac—Hypersensitivity—Goserelin—prostate cancer	0.000364	0.00172	CcSEcCtD
Nepafenac—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000361	0.00171	CcSEcCtD
Nepafenac—Nausea—Ethinyl Estradiol—prostate cancer	0.000357	0.00169	CcSEcCtD
Nepafenac—Eye pain—Doxorubicin—prostate cancer	0.000355	0.00168	CcSEcCtD
Nepafenac—Skin disorder—Mitoxantrone—prostate cancer	0.000354	0.00168	CcSEcCtD
Nepafenac—Pruritus—Goserelin—prostate cancer	0.00035	0.00166	CcSEcCtD
Nepafenac—Pruritus—Conjugated Estrogens—prostate cancer	0.000346	0.00164	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Estradiol—prostate cancer	0.000338	0.0016	CcSEcCtD
Nepafenac—Eye disorder—Docetaxel—prostate cancer	0.000332	0.00157	CcSEcCtD
Nepafenac—Dizziness—Goserelin—prostate cancer	0.000327	0.00155	CcSEcCtD
Nepafenac—Dizziness—Conjugated Estrogens—prostate cancer	0.000324	0.00153	CcSEcCtD
Nepafenac—Angiopathy—Docetaxel—prostate cancer	0.000322	0.00153	CcSEcCtD
Nepafenac—Eye disorder—Capecitabine—prostate cancer	0.000321	0.00152	CcSEcCtD
Nepafenac—Hypertension—Etoposide—prostate cancer	0.000321	0.00152	CcSEcCtD
Nepafenac—Immune system disorder—Docetaxel—prostate cancer	0.000321	0.00152	CcSEcCtD
Nepafenac—Tiaprofenic acid—PTGS2—prostate cancer	0.000315	0.0325	CrCbGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000314	0.00149	CcSEcCtD
Nepafenac—Vomiting—Goserelin—prostate cancer	0.000314	0.00149	CcSEcCtD
Nepafenac—Angiopathy—Capecitabine—prostate cancer	0.000312	0.00148	CcSEcCtD
Nepafenac—Vomiting—Conjugated Estrogens—prostate cancer	0.000311	0.00147	CcSEcCtD
Nepafenac—Immune system disorder—Capecitabine—prostate cancer	0.000311	0.00147	CcSEcCtD
Nepafenac—Headache—Goserelin—prostate cancer	0.00031	0.00147	CcSEcCtD
Nepafenac—Headache—Conjugated Estrogens—prostate cancer	0.000307	0.00145	CcSEcCtD
Nepafenac—Modafinil—CYP3A5—prostate cancer	0.000304	0.0314	CrCbGaD
Nepafenac—Skin disorder—Etoposide—prostate cancer	0.000295	0.0014	CcSEcCtD
Nepafenac—Nausea—Goserelin—prostate cancer	0.000293	0.00139	CcSEcCtD
Nepafenac—Magnesium salicylate—PTGS2—prostate cancer	0.000293	0.0303	CrCbGaD
Nepafenac—Nausea—Conjugated Estrogens—prostate cancer	0.000291	0.00138	CcSEcCtD
Nepafenac—Hypersensitivity—Estradiol—prostate cancer	0.000289	0.00137	CcSEcCtD
Nepafenac—Mebendazole—CYP3A4—prostate cancer	0.000287	0.0296	CrCbGaD
Nepafenac—Fenbufen—PTGS2—prostate cancer	0.000287	0.0296	CrCbGaD
Nepafenac—Eye disorder—Prednisone—prostate cancer	0.000286	0.00136	CcSEcCtD
Nepafenac—Vision blurred—Capecitabine—prostate cancer	0.000282	0.00134	CcSEcCtD
Nepafenac—Angiopathy—Prednisone—prostate cancer	0.000278	0.00132	CcSEcCtD
Nepafenac—Carbamazepine—CYP3A5—prostate cancer	0.000278	0.0287	CrCbGaD
Nepafenac—Oxcarbazepine—CYP2C19—prostate cancer	0.000277	0.0286	CrCbGaD
Nepafenac—Pruritus—Estradiol—prostate cancer	0.000277	0.00131	CcSEcCtD
Nepafenac—Immune system disorder—Prednisone—prostate cancer	0.000277	0.00131	CcSEcCtD
Nepafenac—Hypersensitivity—Mitoxantrone—prostate cancer	0.000269	0.00127	CcSEcCtD
Nepafenac—Hypertension—Docetaxel—prostate cancer	0.000267	0.00126	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Etoposide—prostate cancer	0.000262	0.00124	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000261	0.00124	CcSEcCtD
Nepafenac—Dizziness—Estradiol—prostate cancer	0.000259	0.00123	CcSEcCtD
Nepafenac—Hypertension—Capecitabine—prostate cancer	0.000258	0.00122	CcSEcCtD
Nepafenac—Dry mouth—Docetaxel—prostate cancer	0.000257	0.00122	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000253	0.0012	CcSEcCtD
Nepafenac—Vision blurred—Prednisone—prostate cancer	0.000251	0.00119	CcSEcCtD
Nepafenac—Sinusitis—Epirubicin—prostate cancer	0.00025	0.00119	CcSEcCtD
Nepafenac—Dry mouth—Capecitabine—prostate cancer	0.000249	0.00118	CcSEcCtD
Nepafenac—Salsalate—PTGS2—prostate cancer	0.000249	0.0257	CrCbGaD
Nepafenac—Vomiting—Estradiol—prostate cancer	0.000249	0.00118	CcSEcCtD
Nepafenac—Nervous system disorder—Docetaxel—prostate cancer	0.000247	0.00117	CcSEcCtD
Nepafenac—Headache—Estradiol—prostate cancer	0.000245	0.00116	CcSEcCtD
Nepafenac—Skin disorder—Docetaxel—prostate cancer	0.000245	0.00116	CcSEcCtD
Nepafenac—Nervous system disorder—Capecitabine—prostate cancer	0.00024	0.00113	CcSEcCtD
Nepafenac—Skin disorder—Capecitabine—prostate cancer	0.000237	0.00112	CcSEcCtD
Nepafenac—Nausea—Estradiol—prostate cancer	0.000233	0.0011	CcSEcCtD
Nepafenac—Vomiting—Mitoxantrone—prostate cancer	0.000232	0.0011	CcSEcCtD
Nepafenac—Sinusitis—Doxorubicin—prostate cancer	0.000232	0.0011	CcSEcCtD
Nepafenac—Hypertension—Prednisone—prostate cancer	0.00023	0.00109	CcSEcCtD
Nepafenac—Headache—Mitoxantrone—prostate cancer	0.000229	0.00108	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000225	0.00107	CcSEcCtD
Nepafenac—Eye disorder—Epirubicin—prostate cancer	0.000224	0.00106	CcSEcCtD
Nepafenac—Hypersensitivity—Etoposide—prostate cancer	0.000224	0.00106	CcSEcCtD
Nepafenac—Diclofenac—CYP2E1—prostate cancer	0.000222	0.023	CrCbGaD
Nepafenac—Diclofenac—CYP2C19—prostate cancer	0.00022	0.0227	CrCbGaD
Nepafenac—Diclofenac—CYP1A1—prostate cancer	0.000219	0.0227	CrCbGaD
Nepafenac—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000218	0.00103	CcSEcCtD
Nepafenac—Angiopathy—Epirubicin—prostate cancer	0.000217	0.00103	CcSEcCtD
Nepafenac—Nausea—Mitoxantrone—prostate cancer	0.000217	0.00103	CcSEcCtD
Nepafenac—Immune system disorder—Epirubicin—prostate cancer	0.000216	0.00103	CcSEcCtD
Nepafenac—Pruritus—Etoposide—prostate cancer	0.000215	0.00102	CcSEcCtD
Nepafenac—Nervous system disorder—Prednisone—prostate cancer	0.000213	0.00101	CcSEcCtD
Nepafenac—Skin disorder—Prednisone—prostate cancer	0.000211	0.001	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000211	0.000999	CcSEcCtD
Nepafenac—Eye disorder—Doxorubicin—prostate cancer	0.000207	0.000981	CcSEcCtD
Nepafenac—Modafinil—CYP2C19—prostate cancer	0.000207	0.0214	CrCbGaD
Nepafenac—Fenoprofen—PTGS2—prostate cancer	0.000206	0.0213	CrCbGaD
Nepafenac—Angiopathy—Doxorubicin—prostate cancer	0.000201	0.000953	CcSEcCtD
Nepafenac—Dizziness—Etoposide—prostate cancer	0.000201	0.000951	CcSEcCtD
Nepafenac—Immune system disorder—Doxorubicin—prostate cancer	0.0002	0.000948	CcSEcCtD
Nepafenac—Vision blurred—Epirubicin—prostate cancer	0.000196	0.000931	CcSEcCtD
Nepafenac—Vomiting—Etoposide—prostate cancer	0.000193	0.000914	CcSEcCtD
Nepafenac—Mefenamic acid—PTGS2—prostate cancer	0.000191	0.0197	CrCbGaD
Nepafenac—Headache—Etoposide—prostate cancer	0.00019	0.000901	CcSEcCtD
Nepafenac—Carbamazepine—CYP2C19—prostate cancer	0.000189	0.0195	CrCbGaD
Nepafenac—Hypersensitivity—Docetaxel—prostate cancer	0.000186	0.000881	CcSEcCtD
Nepafenac—Vision blurred—Doxorubicin—prostate cancer	0.000182	0.000861	CcSEcCtD
Nepafenac—Nausea—Etoposide—prostate cancer	0.00018	0.000854	CcSEcCtD
Nepafenac—Hypertension—Epirubicin—prostate cancer	0.00018	0.000853	CcSEcCtD
Nepafenac—Hypersensitivity—Capecitabine—prostate cancer	0.00018	0.000853	CcSEcCtD
Nepafenac—Pruritus—Docetaxel—prostate cancer	0.000178	0.000846	CcSEcCtD
Nepafenac—Oxcarbazepine—CYP3A4—prostate cancer	0.000176	0.0182	CrCbGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000176	0.000835	CcSEcCtD
Nepafenac—Dry mouth—Epirubicin—prostate cancer	0.000174	0.000823	CcSEcCtD
Nepafenac—Pruritus—Capecitabine—prostate cancer	0.000173	0.000819	CcSEcCtD
Nepafenac—Nervous system disorder—Epirubicin—prostate cancer	0.000167	0.000791	CcSEcCtD
Nepafenac—Dizziness—Docetaxel—prostate cancer	0.000167	0.00079	CcSEcCtD
Nepafenac—Hypertension—Doxorubicin—prostate cancer	0.000167	0.000789	CcSEcCtD
Nepafenac—Skin disorder—Epirubicin—prostate cancer	0.000165	0.000783	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000163	0.000773	CcSEcCtD
Nepafenac—Dizziness—Capecitabine—prostate cancer	0.000162	0.000765	CcSEcCtD
Nepafenac—Dry mouth—Doxorubicin—prostate cancer	0.000161	0.000761	CcSEcCtD
Nepafenac—Vomiting—Docetaxel—prostate cancer	0.00016	0.00076	CcSEcCtD
Nepafenac—Hypersensitivity—Prednisone—prostate cancer	0.00016	0.000759	CcSEcCtD
Nepafenac—Headache—Docetaxel—prostate cancer	0.000158	0.000749	CcSEcCtD
Nepafenac—Vomiting—Capecitabine—prostate cancer	0.000155	0.000736	CcSEcCtD
Nepafenac—Nervous system disorder—Doxorubicin—prostate cancer	0.000154	0.000732	CcSEcCtD
Nepafenac—Pruritus—Prednisone—prostate cancer	0.000154	0.000729	CcSEcCtD
Nepafenac—Headache—Capecitabine—prostate cancer	0.000153	0.000725	CcSEcCtD
Nepafenac—Skin disorder—Doxorubicin—prostate cancer	0.000153	0.000725	CcSEcCtD
Nepafenac—Nausea—Docetaxel—prostate cancer	0.00015	0.00071	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000147	0.000696	CcSEcCtD
Nepafenac—Nausea—Capecitabine—prostate cancer	0.000145	0.000687	CcSEcCtD
Nepafenac—Dizziness—Prednisone—prostate cancer	0.000144	0.000682	CcSEcCtD
Nepafenac—Diclofenac—CYP3A4—prostate cancer	0.00014	0.0145	CrCbGaD
Nepafenac—Vomiting—Prednisone—prostate cancer	0.000138	0.000655	CcSEcCtD
Nepafenac—Diclofenac—PTGS2—prostate cancer	0.000137	0.0142	CrCbGaD
Nepafenac—Headache—Prednisone—prostate cancer	0.000136	0.000646	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000136	0.000644	CcSEcCtD
Nepafenac—Modafinil—CYP3A4—prostate cancer	0.000132	0.0136	CrCbGaD
Nepafenac—Nausea—Prednisone—prostate cancer	0.000129	0.000612	CcSEcCtD
Nepafenac—Hypersensitivity—Epirubicin—prostate cancer	0.000125	0.000594	CcSEcCtD
Nepafenac—Ketoprofen—PTGS2—prostate cancer	0.000121	0.0125	CrCbGaD
Nepafenac—Pruritus—Epirubicin—prostate cancer	0.00012	0.00057	CcSEcCtD
Nepafenac—Carbamazepine—CYP3A4—prostate cancer	0.00012	0.0124	CrCbGaD
Nepafenac—Hypersensitivity—Doxorubicin—prostate cancer	0.000116	0.00055	CcSEcCtD
Nepafenac—Dizziness—Epirubicin—prostate cancer	0.000113	0.000533	CcSEcCtD
Nepafenac—Pruritus—Doxorubicin—prostate cancer	0.000111	0.000528	CcSEcCtD
Nepafenac—Vomiting—Epirubicin—prostate cancer	0.000108	0.000513	CcSEcCtD
Nepafenac—Headache—Epirubicin—prostate cancer	0.000107	0.000505	CcSEcCtD
Nepafenac—Dizziness—Doxorubicin—prostate cancer	0.000104	0.000493	CcSEcCtD
Nepafenac—Nausea—Epirubicin—prostate cancer	0.000101	0.000479	CcSEcCtD
Nepafenac—Vomiting—Doxorubicin—prostate cancer	0.0001	0.000474	CcSEcCtD
Nepafenac—Headache—Doxorubicin—prostate cancer	9.86e-05	0.000467	CcSEcCtD
Nepafenac—Nausea—Doxorubicin—prostate cancer	9.35e-05	0.000443	CcSEcCtD
Nepafenac—PTGS2—Disease—RPL12—prostate cancer	6.23e-05	0.000382	CbGpPWpGaD
Nepafenac—PTGS2—Disease—LDHB—prostate cancer	6.23e-05	0.000382	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—TNFRSF21—prostate cancer	6.14e-05	0.000376	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—MTAP—prostate cancer	5.97e-05	0.000366	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP7B1—prostate cancer	5.97e-05	0.000366	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—prostate cancer	5.97e-05	0.000365	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—SLC22A3—prostate cancer	5.95e-05	0.000364	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—HSD3B1—prostate cancer	5.95e-05	0.000364	CbGpPWpGaD
Nepafenac—PTGS2—Disease—TCN2—prostate cancer	5.91e-05	0.000362	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—prostate cancer	5.85e-05	0.000358	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	5.84e-05	0.000357	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—SULT1E1—prostate cancer	5.82e-05	0.000356	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—SRD5A1—prostate cancer	5.82e-05	0.000356	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—LPL—prostate cancer	5.77e-05	0.000353	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTA4—prostate cancer	5.7e-05	0.000349	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—TBXAS1—prostate cancer	5.7e-05	0.000349	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—prostate cancer	5.69e-05	0.000349	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	5.65e-05	0.000346	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—prostate cancer	5.64e-05	0.000345	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	5.57e-05	0.000341	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	5.57e-05	0.000341	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTA2—prostate cancer	5.56e-05	0.00034	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—HSD17B3—prostate cancer	5.55e-05	0.00034	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ACSL4—prostate cancer	5.55e-05	0.00034	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TP53—prostate cancer	5.51e-05	0.000338	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—prostate cancer	5.51e-05	0.000337	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—prostate cancer	5.5e-05	0.000336	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—SULT1A1—prostate cancer	5.49e-05	0.000336	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ABCG5—prostate cancer	5.49e-05	0.000336	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	5.49e-05	0.000336	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTA1—prostate cancer	5.36e-05	0.000328	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ARG2—prostate cancer	5.32e-05	0.000326	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PHGDH—prostate cancer	5.32e-05	0.000326	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—UMPS—prostate cancer	5.32e-05	0.000326	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTO1—prostate cancer	5.3e-05	0.000325	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—HSD3B2—prostate cancer	5.3e-05	0.000325	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—NAT2—prostate cancer	5.3e-05	0.000325	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	5.3e-05	0.000324	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—prostate cancer	5.24e-05	0.000321	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—LDHB—prostate cancer	5.22e-05	0.00032	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP3A5—prostate cancer	5.13e-05	0.000314	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	5.1e-05	0.000312	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—prostate cancer	5.1e-05	0.000312	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PLCB2—prostate cancer	5.08e-05	0.000311	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—LRP2—prostate cancer	5.08e-05	0.000311	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP2C18—prostate cancer	5.08e-05	0.000311	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—IL6—prostate cancer	5.05e-05	0.000309	CbGpPWpGaD
Nepafenac—PTGS2—Disease—GSTO1—prostate cancer	5.03e-05	0.000308	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—P4HB—prostate cancer	4.98e-05	0.000305	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—prostate cancer	4.96e-05	0.000304	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PDHA1—prostate cancer	4.95e-05	0.000303	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—TCN2—prostate cancer	4.95e-05	0.000303	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTA3—prostate cancer	4.95e-05	0.000303	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—UCP3—prostate cancer	4.95e-05	0.000303	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—SLC22A1—prostate cancer	4.85e-05	0.000297	CbGpPWpGaD
Nepafenac—PTGS2—Disease—LRP2—prostate cancer	4.82e-05	0.000295	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	4.79e-05	0.000293	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—SULT2A1—prostate cancer	4.73e-05	0.000289	CbGpPWpGaD
Nepafenac—PTGS2—Disease—P4HB—prostate cancer	4.73e-05	0.000289	CbGpPWpGaD
Nepafenac—PTGS2—Disease—RPL10—prostate cancer	4.73e-05	0.000289	CbGpPWpGaD
Nepafenac—PTGS2—Disease—EIF2AK2—prostate cancer	4.73e-05	0.000289	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—HSD3B1—prostate cancer	4.72e-05	0.000289	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—SLC22A3—prostate cancer	4.72e-05	0.000289	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—MED12—prostate cancer	4.65e-05	0.000285	CbGpPWpGaD
Nepafenac—PTGS2—Disease—HIST1H2BG—prostate cancer	4.64e-05	0.000284	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GNG5—prostate cancer	4.61e-05	0.000282	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—LPL—prostate cancer	4.58e-05	0.000281	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—prostate cancer	4.57e-05	0.00028	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—prostate cancer	4.56e-05	0.000279	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—TBXAS1—prostate cancer	4.53e-05	0.000277	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTA4—prostate cancer	4.53e-05	0.000277	CbGpPWpGaD
Nepafenac—PTGS2—Disease—HIST1H4H—prostate cancer	4.48e-05	0.000274	CbGpPWpGaD
Nepafenac—PTGS2—Disease—NPPA—prostate cancer	4.48e-05	0.000274	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—prostate cancer	4.47e-05	0.000273	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—NCOA3—prostate cancer	4.44e-05	0.000272	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	4.42e-05	0.000271	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTA2—prostate cancer	4.41e-05	0.00027	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	4.37e-05	0.000267	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—SULT1A1—prostate cancer	4.36e-05	0.000267	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ABCG5—prostate cancer	4.36e-05	0.000267	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTA1—prostate cancer	4.26e-05	0.000261	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—HPGDS—prostate cancer	4.24e-05	0.00026	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—prostate cancer	4.22e-05	0.000258	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP2C19—prostate cancer	4.21e-05	0.000258	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—NAT2—prostate cancer	4.21e-05	0.000258	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTO1—prostate cancer	4.21e-05	0.000258	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—HSD3B2—prostate cancer	4.21e-05	0.000258	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTT1—prostate cancer	4.11e-05	0.000252	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ACHE—prostate cancer	4.11e-05	0.000252	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP2A6—prostate cancer	4.06e-05	0.000249	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	4.05e-05	0.000248	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	4.05e-05	0.000248	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PLCB2—prostate cancer	4.04e-05	0.000247	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—LRP2—prostate cancer	4.04e-05	0.000247	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP2C18—prostate cancer	4.04e-05	0.000247	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—P4HB—prostate cancer	3.96e-05	0.000242	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—AKR1C3—prostate cancer	3.95e-05	0.000242	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PRKACB—prostate cancer	3.93e-05	0.000241	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP17A1—prostate cancer	3.89e-05	0.000238	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	3.88e-05	0.000237	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—SLC22A1—prostate cancer	3.85e-05	0.000236	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	3.84e-05	0.000235	CbGpPWpGaD
Nepafenac—PTGS2—Disease—B2M—prostate cancer	3.81e-05	0.000233	CbGpPWpGaD
Nepafenac—PTGS2—Disease—TGFBR1—prostate cancer	3.81e-05	0.000233	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	3.81e-05	0.000233	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—SULT2A1—prostate cancer	3.75e-05	0.00023	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	3.75e-05	0.00023	CbGpPWpGaD
Nepafenac—PTGS2—Disease—RPS19—prostate cancer	3.75e-05	0.000229	CbGpPWpGaD
Nepafenac—PTGS2—Disease—AKR1C3—prostate cancer	3.75e-05	0.000229	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PRKACB—prostate cancer	3.73e-05	0.000228	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—NCOA2—prostate cancer	3.71e-05	0.000227	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—MED12—prostate cancer	3.69e-05	0.000226	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GNG5—prostate cancer	3.66e-05	0.000224	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PPP3CA—prostate cancer	3.63e-05	0.000222	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—SLC5A5—prostate cancer	3.54e-05	0.000217	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—NCOA3—prostate cancer	3.53e-05	0.000216	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PRKCZ—prostate cancer	3.52e-05	0.000215	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	3.47e-05	0.000212	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP2E1—prostate cancer	3.46e-05	0.000212	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CALR—prostate cancer	3.45e-05	0.000211	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—NQO1—prostate cancer	3.42e-05	0.000209	CbGpPWpGaD
Nepafenac—PTGS2—Disease—FGFR4—prostate cancer	3.39e-05	0.000208	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PARP1—prostate cancer	3.39e-05	0.000208	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—TH—prostate cancer	3.37e-05	0.000206	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—HPGDS—prostate cancer	3.36e-05	0.000206	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CALCA—prostate cancer	3.35e-05	0.000205	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.35e-05	0.000205	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP2C19—prostate cancer	3.34e-05	0.000205	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP3A4—prostate cancer	3.33e-05	0.000204	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.31e-05	0.000203	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP1B1—prostate cancer	3.28e-05	0.000201	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ACHE—prostate cancer	3.26e-05	0.0002	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTT1—prostate cancer	3.26e-05	0.0002	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP2A6—prostate cancer	3.23e-05	0.000198	CbGpPWpGaD
Nepafenac—PTGS2—Disease—HSPA1A—prostate cancer	3.21e-05	0.000197	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	3.21e-05	0.000197	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GGT1—prostate cancer	3.17e-05	0.000194	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	3.17e-05	0.000194	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—AKR1C3—prostate cancer	3.14e-05	0.000192	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—NCOA1—prostate cancer	3.12e-05	0.000191	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PRKACB—prostate cancer	3.12e-05	0.000191	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP17A1—prostate cancer	3.09e-05	0.000189	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CASP9—prostate cancer	3.08e-05	0.000189	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP19A1—prostate cancer	3.08e-05	0.000189	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	3.05e-05	0.000187	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PRKCQ—prostate cancer	2.99e-05	0.000183	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—RXRA—prostate cancer	2.97e-05	0.000182	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—NCOA2—prostate cancer	2.94e-05	0.00018	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.89e-05	0.000177	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—COMT—prostate cancer	2.86e-05	0.000175	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTP1—prostate cancer	2.85e-05	0.000174	CbGpPWpGaD
Nepafenac—PTGS2—Disease—FGF10—prostate cancer	2.84e-05	0.000174	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—SLC5A5—prostate cancer	2.81e-05	0.000172	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ITPR1—prostate cancer	2.8e-05	0.000172	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.76e-05	0.000169	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP2E1—prostate cancer	2.74e-05	0.000168	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—NQO1—prostate cancer	2.71e-05	0.000166	CbGpPWpGaD
Nepafenac—PTGS2—Disease—TGFBR2—prostate cancer	2.7e-05	0.000165	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—TH—prostate cancer	2.67e-05	0.000164	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ITPR1—prostate cancer	2.66e-05	0.000163	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.66e-05	0.000163	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—TYMS—prostate cancer	2.65e-05	0.000162	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP3A4—prostate cancer	2.64e-05	0.000162	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTM1—prostate cancer	2.62e-05	0.00016	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP1B1—prostate cancer	2.6e-05	0.000159	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—LPL—prostate cancer	2.57e-05	0.000157	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GGT1—prostate cancer	2.52e-05	0.000154	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP1A1—prostate cancer	2.48e-05	0.000152	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—NCOA1—prostate cancer	2.48e-05	0.000152	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ERCC2—prostate cancer	2.46e-05	0.000151	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP19A1—prostate cancer	2.44e-05	0.00015	CbGpPWpGaD
Nepafenac—PTGS2—Disease—LPL—prostate cancer	2.44e-05	0.000149	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PDGFRB—prostate cancer	2.41e-05	0.000148	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—RXRA—prostate cancer	2.36e-05	0.000144	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ERCC2—prostate cancer	2.33e-05	0.000143	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—MTHFR—prostate cancer	2.31e-05	0.000142	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.29e-05	0.000141	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ERBB3—prostate cancer	2.28e-05	0.00014	CbGpPWpGaD
Nepafenac—PTGS2—Disease—FGFR2—prostate cancer	2.28e-05	0.00014	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—COMT—prostate cancer	2.27e-05	0.000139	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PPARA—prostate cancer	2.27e-05	0.000139	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTP1—prostate cancer	2.26e-05	0.000138	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ITPR1—prostate cancer	2.23e-05	0.000136	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MTHFR—prostate cancer	2.19e-05	0.000134	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	2.19e-05	0.000134	CbGpPWpGaD
Nepafenac—PTGS2—Disease—TERT—prostate cancer	2.19e-05	0.000134	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CAV1—prostate cancer	2.13e-05	0.000131	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—TYMS—prostate cancer	2.1e-05	0.000129	CbGpPWpGaD
Nepafenac—PTGS2—Disease—HIF1A—prostate cancer	2.09e-05	0.000128	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTM1—prostate cancer	2.08e-05	0.000127	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—LPL—prostate cancer	2.04e-05	0.000125	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.04e-05	0.000125	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CAV1—prostate cancer	2.02e-05	0.000124	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP1A1—prostate cancer	1.97e-05	0.000121	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ERCC2—prostate cancer	1.95e-05	0.00012	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PIK3CG—prostate cancer	1.94e-05	0.000119	CbGpPWpGaD
Nepafenac—PTGS2—Disease—BAD—prostate cancer	1.9e-05	0.000117	CbGpPWpGaD
Nepafenac—PTGS2—Disease—APC—prostate cancer	1.84e-05	0.000113	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—INS—prostate cancer	1.84e-05	0.000113	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—MTHFR—prostate cancer	1.84e-05	0.000112	CbGpPWpGaD
Nepafenac—PTGS2—Disease—EGF—prostate cancer	1.82e-05	0.000112	CbGpPWpGaD
Nepafenac—PTGS2—Disease—IRS1—prostate cancer	1.82e-05	0.000112	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CREBBP—prostate cancer	1.8e-05	0.00011	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PPARA—prostate cancer	1.8e-05	0.00011	CbGpPWpGaD
Nepafenac—PTGS2—Disease—GSK3B—prostate cancer	1.77e-05	0.000108	CbGpPWpGaD
Nepafenac—PTGS2—Disease—INS—prostate cancer	1.74e-05	0.000107	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PIK3CD—prostate cancer	1.71e-05	0.000105	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CREBBP—prostate cancer	1.71e-05	0.000105	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CAV1—prostate cancer	1.69e-05	0.000104	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MAP2K1—prostate cancer	1.63e-05	9.99e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PIK3CD—prostate cancer	1.62e-05	9.92e-05	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.62e-05	9.91e-05	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—NOS3—prostate cancer	1.61e-05	9.88e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—SERPINE1—prostate cancer	1.6e-05	9.81e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—FGF2—prostate cancer	1.55e-05	9.5e-05	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PIK3CG—prostate cancer	1.54e-05	9.45e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—NOS3—prostate cancer	1.53e-05	9.37e-05	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PIK3CB—prostate cancer	1.49e-05	9.12e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—JAK2—prostate cancer	1.49e-05	9.1e-05	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PTGS2—prostate cancer	1.48e-05	9.04e-05	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—INS—prostate cancer	1.46e-05	8.95e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MDM2—prostate cancer	1.45e-05	8.89e-05	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CREBBP—prostate cancer	1.43e-05	8.76e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—ERBB2—prostate cancer	1.43e-05	8.76e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PIK3CB—prostate cancer	1.41e-05	8.65e-05	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PIK3CD—prostate cancer	1.36e-05	8.31e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CDKN1B—prostate cancer	1.33e-05	8.11e-05	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PTEN—prostate cancer	1.29e-05	7.88e-05	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—NOS3—prostate cancer	1.28e-05	7.84e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CTNNB1—prostate cancer	1.25e-05	7.67e-05	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—EP300—prostate cancer	1.23e-05	7.52e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CDKN1A—prostate cancer	1.22e-05	7.49e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PTEN—prostate cancer	1.22e-05	7.47e-05	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PIK3CB—prostate cancer	1.18e-05	7.24e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—EP300—prostate cancer	1.16e-05	7.13e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—SRC—prostate cancer	1.13e-05	6.93e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—STAT3—prostate cancer	1.09e-05	6.68e-05	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PTEN—prostate cancer	1.02e-05	6.26e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MYC—prostate cancer	1.01e-05	6.21e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—TGFB1—prostate cancer	1.01e-05	6.19e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—EGFR—prostate cancer	9.92e-06	6.07e-05	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—EP300—prostate cancer	9.75e-06	5.97e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—KRAS—prostate cancer	9.37e-06	5.74e-05	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PIK3CA—prostate cancer	9.08e-06	5.56e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—PIK3CA—prostate cancer	8.61e-06	5.27e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—IL6—prostate cancer	7.62e-06	4.67e-05	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—AKT1—prostate cancer	7.42e-06	4.54e-05	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—PIK3CA—prostate cancer	7.21e-06	4.41e-05	CbGpPWpGaD
Nepafenac—PTGS2—Disease—AKT1—prostate cancer	7.03e-06	4.31e-05	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—AKT1—prostate cancer	5.89e-06	3.61e-05	CbGpPWpGaD
